Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?

About this episode

A panel of industry experts discusses the future of biologic therapeutics, focusing on the potential of half-life extended peptides versus multispecific antibodies.

During last year’s PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics, followed by a conversation featuring Paul Carter, Ph.D., Genentech Fellow of Antibody Engineering, G. Jonah Rainey, Ph.D., associate vice president of Eli Lilly and Company, and Janine Schuurman, Ph.D., biotech consultant at Lust for Life Science B.V. Moderate...

People in this episode

Guests: Paul Carter, G. Jonah Rainey, Janine Schuurman

Topics covered

• biologic therapeutics
• monoclonal antibodies
• peptides
• antibody engineering
• biotechnology

Keywords

• biologics
• therapeutics
• peptides
• antibodies
• biotechnology
• panel discussion
• monoclonal antibodies

Mentioned in this episode

Organizations: Genentech, Eli Lilly and Company, Lust for Life Science B.V.

More episodes of The Chain: Protein Engineering Podcast

• Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D · June 9, 2026 · 54 min
• Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating · May 12, 2026 · 47 min
• Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design · April 15, 2026 · 39 min
• Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement · March 17, 2026 · 59 min
• Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research · January 13, 2026 · 44 min
• Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity · December 9, 2025 · 27 min